This application is to renew the NCI Cancer Center P30 Support Grant for the Cancer Therapy &Research Center (CTRC) at the University of Texas Health Science Center at San Antonio (UTHSCSA) for years 17-21. The CTRC at UTHSCSA merged with the formerly-independent CTRC to form this new entity (hereinafter called """"""""CTRC""""""""). This merger, in the form of a $150 million gift, the largest gift in UTHSCSA history, and among the largest in University of Texas history, brings full alignment to our Cancer Center activities. With this merger and realignment, the CTRC has re-entered a period of significant growth and improvement in the quality of its clinical, basic, translational and population-based research programs. Our NCI funding base has increased from $8,453,756 in 2006 to $11,050,146 in 2007. We serve a vast geographic region in and around San Antonio and South Texas, larger than the state of Pennsylvania and comprising 4.4 million inhabitants. Our population is predominantly Hispanic and dominated by individuals in lower socioeconomic strata with the lowest rates of health insurance coverage in the nation. We have worked to serve the disadvantaged for years, and are now also re-focusing more research and clinical efforts to understand better the specific cancer-related risks and disease patterns in Hispanics, and to serve the needs of our citizens better. We have significant community outreach, wellness and cancer screening programs reaching these disadvantaged populations. These efforts are greatly helped in that leaders in our Cancer Center and at UTHSCSA are Hispanic. We request support for three research programs, ten shared resources, seven senior leaders, one staff investigator, modest developmental funds, and commensurate administrative support. Our three research programs are Cancer Prevention and Population Sciences, Experimental and Developmental Therapeutics, and Cancer Development and Progression. Our shared resources are Antibody, Biostatistics and Informatics, Flow Cytometry, Genomics, Macromolecular Interactions, Macromolecular Structure, Mass Spectrometry, Optical Imaging, Pathology, and Research Administration. The CTRC will continue its record of promoting inter-programmatic and intra-programmatic collaborations, and strategic use of developmental funds, in combination with significant institutional commitment and a successful record of philanthropic support that in sum ensures a synergistic return on investment not possible without the P30 infrastructure and guidance.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA054174-19S6
Application #
8709458
Study Section
Subcommittee G - Education (NCI)
Program Officer
Shafik, Hasnaa
Project Start
1997-08-01
Project End
2014-07-31
Budget Start
2013-08-01
Budget End
2014-07-31
Support Year
19
Fiscal Year
2013
Total Cost
$75,000
Indirect Cost
$24,833
Name
University of Texas Health Science Center San Antonio
Department
Urology
Type
Schools of Medicine
DUNS #
800772162
City
San Antonio
State
TX
Country
United States
Zip Code
78229
Newcomb, Lisa F; Thompson Jr, Ian M; Boyer, Hilary D et al. (2016) Outcomes of Active Surveillance for Clinically Localized Prostate Cancer in the Prospective, Multi-Institutional Canary PASS Cohort. J Urol 195:313-20
Zanotto-Filho, Alfeu; Dashnamoorthy, Ravi; Loranc, Eva et al. (2016) Combined Gene Expression and RNAi Screening to Identify Alkylation Damage Survival Pathways from Fly to Human. PLoS One 11:e0153970
Price, Douglas K; Chau, Cindy H; Till, Cathee et al. (2016) Association of androgen metabolism gene polymorphisms with prostate cancer risk and androgen concentrations: Results from the Prostate Cancer Prevention Trial. Cancer 122:2332-40
Ortiz, Carmen; Morales, Luisa; Sastre, Miguel et al. (2016) Cytotoxicity and Genotoxicity Assessment of Sandalwood Essential Oil in Human Breast Cell Lines MCF-7 and MCF-10A. Evid Based Complement Alternat Med 2016:3696232
Sareddy, Gangadhara R; Li, Xiaonan; Liu, Jinyou et al. (2016) Selective Estrogen Receptor β Agonist LY500307 as a Novel Therapeutic Agent for Glioblastoma. Sci Rep 6:24185
Zanotto-Filho, Alfeu; Masamsetti, V Pragathi; Loranc, Eva et al. (2016) Alkylating Agent-Induced NRF2 Blocks Endoplasmic Reticulum Stress-Mediated Apoptosis via Control of Glutathione Pools and Protein Thiol Homeostasis. Mol Cancer Ther 15:3000-3014
Schenk, Jeannette M; Till, Cathee; Hsing, Ann W et al. (2016) Serum androgens and prostate cancer risk: results from the placebo arm of the Prostate Cancer Prevention Trial. Cancer Causes Control 27:175-82
Sweeney, Shannon R; Kavanaugh, Arthur; Lodi, Alessia et al. (2016) Metabolomic profiling predicts outcome of rituximab therapy in rheumatoid arthritis. RMD Open 2:e000289
Wu, Anqi; Dong, Qiaoxiang; Gao, Hui et al. (2016) Characterization of mammary epithelial stem/progenitor cells and their changes with aging in common marmosets. Sci Rep 6:32190
Toledo, Rodrigo A; Qin, Yuejuan; Cheng, Zi-Ming et al. (2016) Recurrent Mutations of Chromatin-Remodeling Genes and Kinase Receptors in Pheochromocytomas and Paragangliomas. Clin Cancer Res 22:2301-10

Showing the most recent 10 out of 853 publications